{"schema_version":"secwatch.filing_event.v1","accession":"0001606498-26-000002","form_type":"8-K","ticker":"AVNS","cik":"0001606498","company_name":"AVANOS MEDICAL, INC.","filed_at":"2026-02-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.627420+00:00","generated_at":"2026-05-16T00:48:41.721269+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Avanos reports Q4 adjusted EPS $0.29 vs $0.43 prior year; FY2025 sales $701.2M up 1.9%","bullets":["Q4 net sales $180.9M (+0.7% YoY); SNS segment up 8.7% to $115.1M; PM&R up 1.3% to $61.6M.","Q4 GAAP net loss $1.3M ($0.03 loss per share); adjusted net income $13.4M ($0.29 adjusted EPS).","Full-year 2025 net loss $72.9M; adjusted EBITDA $86.8M vs $107.6M in 2024.","Recorded $77M non-cash goodwill impairment on PM&R segment in Q2 2025.","2026 guidance: net sales $700-720M; adjusted diluted EPS $0.90-1.10."],"urls":{"canonical":"https://secwatch.observer/filing/0001606498-26-000002","json":"https://secwatch.observer/filing/0001606498-26-000002.json","markdown":"https://secwatch.observer/filing/0001606498-26-000002.md","text":"https://secwatch.observer/filing/0001606498-26-000002.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1606498/000160649826000002/0001606498-26-000002-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1606498/000160649826000002/avns-20260224.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T00:48:41.721269+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}